MCID: CLL003
MIFTS: 53

Cellulitis

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Cellulitis

MalaCards integrated aliases for Cellulitis:

Name: Cellulitis 12 54 42 44 15 17 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:3488
MeSH 44 D002481
SNOMED-CT 67 267833003 74276003
ICD10 32 L03 L03.9 L03.90
UMLS 70 C0007642 C0007646

Summaries for Cellulitis

MedlinePlus : 42 Cellulitis is an infection of the skin and deep underlying tissues. Group A strep (streptococcal) bacteria are the most common cause. The bacteria enter your body when you get an injury such as a bruise, burn, surgical cut, or wound. Symptoms include Fever and chills Swollen glands or lymph nodes A rash with painful, red, tender skin. The skin may blister and scab over. Your health care provider may take a sample or culture from your skin or do a blood test to identify the bacteria causing infection. Treatment is with antibiotics. They may be oral in mild cases, or intravenous (by IV) for more severe cases.

MalaCards based summary : Cellulitis is related to orbital cellulitis and wells syndrome, and has symptoms including fever, pruritus and exanthema. An important gene associated with Cellulitis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetylcysteine and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and breast, and related phenotypes are digestive/alimentary and immune system

Disease Ontology : 12 A skin disease where there is a diffuse infection of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin. Cellulitis can be caused by normal skin flora or by exogenous bacteria, and often occurs where the skin has previously been broken: cracks in the skin, cuts, blisters, burns, insect bites, surgical wounds, or sites of intravenous catheter insertion.

Wikipedia : 73 Cellulitis is a bacterial infection involving the inner layers of the skin. It specifically affects the... more...

Related Diseases for Cellulitis

Diseases related to Cellulitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1239)
# Related Disease Score Top Affiliating Genes
1 orbital cellulitis 32.8 IGES CRP CD4
2 wells syndrome 32.4 RNASE3 IL5 IL1R1 CRP
3 tinea unguium 32.4 GPT CRP
4 parametritis 32.1 IL5 F2 CRP ALB
5 erysipelas 31.8 TNF MYOM2 IL6 CRP
6 nocardiosis 31.7 TNF LACTB CRP CD4
7 haemophilus influenzae 31.3 TNF LACTB
8 fasciitis 31.2 TNF MYOM2 IL6
9 cavernous sinus thrombosis 31.0 F2 CRP
10 dermatophytosis 30.9 DEFB4A CD4 CCR6
11 cryptococcosis 30.9 TNF CD4 CCR6
12 osteomyelitis 30.8 TNF IL6 CSF3 CRP
13 panophthalmitis 30.8 CRP CD4
14 lymphangitis 30.7 FLT4 CRP CD4
15 maxillary sinusitis 30.7 RNASE3 LACTB CRP
16 thrombophlebitis 30.7 F2 CRP ALB
17 necrotizing fasciitis 30.7 MYOM2 IL6 CRP CAMP ALB
18 conjunctivitis 30.7 TNF RNASE3 IL6 IL5
19 toxic shock syndrome 30.6 TNF MYOM2 IL6 IL1R1 CRP
20 endophthalmitis 30.6 TNF IL6 CRP ALB
21 septic arthritis 30.6 TNF DEFB4A CRP
22 neutrophilic dermatosis, acute febrile 30.5 TNF CSF3 CRP
23 panniculitis 30.5 TNF CSF3 CRP CD4
24 lymphadenitis 30.5 TNF CRP CD4 CCR6
25 ecthyma 30.5 MYOM2 CSF3 CRP
26 erythema nodosum 30.5 TNF IL6 CRP
27 subdural empyema 30.5 F2 CRP
28 posterior scleritis 30.4 TNF CRP
29 scleritis 30.4 TNF IL5 CRP CCR6
30 pyoderma gangrenosum 30.4 TNF IL1R1 CSF3 CCR6
31 folliculitis 30.4 IL5 DEFB4A CD4 CCR6
32 lemierre's syndrome 30.4 F2 CRP
33 pustulosis of palm and sole 30.3 TNF CRP CCR6
34 keratitis, hereditary 30.3 TNF IL6 CD4 CCR6
35 mediastinitis 30.3 LACTB F2 CRP CD4 ALB
36 herpes zoster 30.3 TNF CD4 CCR6
37 peritonitis 30.3 TNF IL6 F2 CRP ALB
38 purpura 30.3 TNF IL6 F2 CRP
39 uvulitis 30.3 GPT CRP
40 gout 30.3 TNF IL6 IL1R1 ALB
41 sarcoidosis 1 30.3 TNF CRP CHI3L1 CD4 CCR6
42 pyomyositis 30.3 MYOM2 CSF3 CRP CD4
43 peripheral vascular disease 30.2 IL6 F2 CRP ALB
44 streptococcal toxic-shock syndrome 30.2 TNF MYOM2 IL6
45 otitis externa 30.2 IL6 CRP CD4
46 mucormycosis 30.2 CSF3 CRP CD4 CCR6 ALB
47 retinal artery occlusion 30.2 IL6 F2 CRP
48 histoplasmosis 30.2 TNF CD4 CCR6
49 melioidosis 30.2 TNF IL6 CSF3
50 brucellosis 30.2 TNF IL6 CRP

Graphical network of the top 20 diseases related to Cellulitis:



Diseases related to Cellulitis

Symptoms & Phenotypes for Cellulitis

UMLS symptoms related to Cellulitis:


fever; pruritus; exanthema

MGI Mouse Phenotypes related to Cellulitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 ALB CD4 F2 FLT4 IL1R1 IL5
2 immune system MP:0005387 9.47 ALB CAMP CCR6 CD4 CHI3L1 CRP

Drugs & Therapeutics for Cellulitis

Drugs for Cellulitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
3
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
4
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
5
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
6
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
7
Retapamulin Approved Phase 4 224452-66-8 6918462
8
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430 439542
9
Vancomycin Approved Phase 4 1404-90-6 14969 441141
10
Dalbavancin Approved, Investigational Phase 4 171500-79-1, 91097-81-3 122186
11
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
12
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
13 Respiratory System Agents Phase 4
14 Antidotes Phase 4
15 diuretics Phase 4
16 Expectorants Phase 4
17 Antioxidants Phase 4
18 Liver Extracts Phase 4
19 N-monoacetylcystine Phase 4
20 Protective Agents Phase 4
21 penicillins Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Antibiotics, Antitubercular Phase 4
24 methicillin Phase 4
25 Anti-Bacterial Agents Phase 4
26 Anti-Infective Agents Phase 4
27 Floxacillin Phase 4
28
Cefazolin Approved Phase 3 25953-19-9 33255 656510
29
Probenecid Approved, Investigational Phase 3 57-66-9 4911
30
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
31
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
32
Ofloxacin Approved Phase 2, Phase 3 82419-36-1 4583
33
Ciprofloxacin Approved, Investigational Phase 2, Phase 3 85721-33-1 2764
34
Levofloxacin Approved, Investigational Phase 2, Phase 3 100986-85-4 149096
35
Cilastatin Approved, Investigational Phase 3 82009-34-5 5280454 6435415
36
Imipenem Approved Phase 3 64221-86-9, 74431-23-5 104838
37
Meropenem Approved, Investigational Phase 3 119478-56-7, 96036-03-2 441130 64778
38
Fusidic Acid Approved, Investigational Phase 3 6990-06-3 3000226
39
Telavancin Approved Phase 3 372151-71-8
40
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
41
Oritavancin Approved, Investigational Phase 3 171099-57-3 16129632
42
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 3 439-14-5 3016
43
Ceftobiprole Approved, Investigational Phase 3 209467-52-7 6918430
44
Ceftazidime Approved Phase 3 78439-06-2, 72558-82-8 5481173
45
Ethanol Approved Phase 3 64-17-5 702
46
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
47
Metronidazole Approved Phase 3 443-48-1 4173
48
Oxacillin Approved, Investigational Phase 3 66-79-5 6196
49
Cefadroxil Approved, Vet_approved, Withdrawn Phase 3 66592-87-8, 50370-12-2 47965 2610
50
Teicoplanin Approved, Investigational Phase 3 61036-62-2

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
2 A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis Unknown status NCT01876628 Phase 4 Flucloxacillin and Clindamycin;Flucloxacillin and placebo
3 Oral Flucloxacillin Alone Versus Flucloxacillin and Phenoxymethylpenicillin for the Emergency Department Outpatient Treatment of Cellulitis: a Non-inferiority Randomised Controlled Trial. Unknown status NCT02922686 Phase 4 Flucloxacillin;Phenoxymethylpenicillin;Placebo (for phenoxymethylpenicillin)
4 Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Unknown status NCT02566928 Phase 4 2% mupirocin ointment
5 Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I) Completed NCT00552799 Phase 4 Penicillin VK
6 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections Completed NCT01549613 Phase 4 Daptomycin;Vancomycin
7 A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
8 Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin Completed NCT01626560 Phase 4 Daptomycin;Vancomycin
9 Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Completed NCT00352612 Phase 4 clindamycin;cephalexin
10 The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown Completed NCT03929224 Phase 4 Medicinal honey and bacitracin;Bacitracin
11 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
12 A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA) Completed NCT01419184 Phase 4 Daptomycin;Vancomycin
13 Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus Completed NCT02582203 Phase 4 Ceftaroline;Vancomycin
14 Randomized Clinical Trial of Wound Packing Following Incision and Drainage of Superficial Skin Abscesses in the Pediatric Emergency Department Completed NCT00746109 Phase 4
15 Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Recruiting NCT03372941 Phase 4 Dalbavancin
16 Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis Terminated NCT02032654 Phase 4 Flucloxacillin;Placebo (for flucloxacillin)
17 A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA) Terminated NCT00463801 Phase 4 Daptomycin
18 Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department Unknown status NCT00323219 Phase 3 Cefazolin and Moxifloxacin
19 A Pilot Randomized Controlled Trial Assessing the Effectiveness of Alcohol Swabs in Preventing Infections in Pediatric Patients Receiving Vaccinations Unknown status NCT03131843 Phase 3 Alcohol;No alcohol
20 Randomized Placebo-Controlled Trial of Bactrim on 7 Day Outcome in Emergency Department Patients With Uncomplicated Abscesses at Risk for Community Acquired Methicillin Resistant Staph Aureus Completed NCT00973765 Phase 3 bactrim;placebo
21 A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities Completed NCT01499277 Phase 3 Ceftaroline fosamil;Vancomycin;Aztreonam
22 A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Levofloxacin Versus Ciprofloxacin HCl in the Treatment of Mild to Moderate Skin and Skin Structure Infections in Adults Completed NCT00257036 Phase 2, Phase 3 levofloxacin
23 A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections. Completed NCT00619710 Phase 3 Meropenem;Imipenem-cilastatin
24 Clinical and Instrumental Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market: Comparison Within Subjects (Double Blind Study) Completed NCT02195297 Phase 3
25 An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
26 A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00091819 Phase 3 Telavancin;Vancomycin
27 The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy. Completed NCT03556917 Phase 2, Phase 3
28 A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II) Completed NCT01252732 Phase 3 Single-Dose IV Oritavancin Diphosphate;IV Vancomycin
29 A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00107978 Phase 3 Telavancin;Vancomycin
30 Ultrasound Guided Needle Drainage Versus Formal Incision and Drainage of Superficial Soft Tissue Abscesses in the Emergency Department Setting Completed NCT01085929 Phase 3
31 A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections Completed NCT00228982 Phase 3 Ceftobiprole medocaril;Vancomycin
32 A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections Completed NCT00210899 Phase 3 ceftobiprole medocaril;Vancomycin plus Ceftazidime
33 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT01431339 Phase 3 IV Dalbavancin;Vancomycin/Linezolid
34 Evaluation of Novel Antimicrobial Hand Towels Completed NCT02512614 Phase 2, Phase 3
35 A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3 ACZ885;Placebo
36 A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I) Completed NCT01252719 Phase 3 Single-Dose IV Oritavancin Diphosphate;IV Vancomycin
37 A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care Completed NCT00560599 Phase 3 mupirocin and chlorhexidine;mupirocin, chlorhexidine, & household cleaning/disinfection
38 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT01339091 Phase 3 Dalbavancin;Vancomycin / Linezolid
39 An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan Completed NCT00991146 Phase 3 canakinumab
40 An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3 Canakinumab (ACZ885)
41 An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01576367 Phase 3
42 A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01302860 Phase 3 ACZ885
43 A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL Completed NCT00684177 Phase 3 Retapamulin Ointment, 1%;Placebo ointment
44 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
45 A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT02127970 Phase 3 Dalbavancin;Dalbavancin-matching Placebo
46 A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections Recruiting NCT02814916 Phase 3 Dalbavancin single dose;Dalbavancin two dose;Comparator
47 A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities. Terminated NCT02202135 Phase 3 Ceftaroline fosamil;Vancomycin;Aztreonam
48 A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection Completed NCT01128530 Phase 2 JNJ-32729463;linezolid;JNJ-32729463 placebo;linezolid placebo
49 A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer Completed NCT01770509 Phase 1, Phase 2
50 Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial Completed NCT01029782 Phase 2 IV cefazolin plus oral probenecid and placebo cephalexin;Oral cephalexin and saline IV plus probenecid placebo

Search NIH Clinical Center for Cellulitis

Cochrane evidence based reviews: cellulitis

Genetic Tests for Cellulitis

Anatomical Context for Cellulitis

MalaCards organs/tissues related to Cellulitis:

40
Skin, Eye, Breast, Lymph Node, Spinal Cord, Bone Marrow, Bone

Publications for Cellulitis

Articles related to Cellulitis:

(show top 50) (show all 9209)
# Title Authors PMID Year
1
Five Predictors Affecting the Prognosis of Patients with Severe Odontogenic Infections. 42 61
33266250 2020
2
Inequitable access to an outpatient parenteral antimicrobial therapy service: linked cross-sectional study. 42 61
32873291 2020
3
Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio in patients with cellulitis. 61 42
32935801 2020
4
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 61 54
16965327 2006
5
Co-relationship between Escherichia coli in broiler cellulitis and liver lesions. 61
32965333 2021
6
Allergic fungal rhinosinusitis presenting with intracranial spread along large sphenoidal emissary foramen. 61
33511029 2021
7
Repeated sinus CT imaging after recent head imaging. 61
33310405 2021
8
Severe cellulitis caused by Achromobacter xylosoxidans after allogeneic hematopoietic stem cell transplantation. 61
33468424 2021
9
Measuring complications of serious pediatric emergencies using ICD-10. 61
33374034 2021
10
Explantation in Tissue Expander and Direct-to-Implant Reconstruction with Acellular Dermal Matrix: How to Avoid Early Reconstructive Failures. 61
33710042 2021
11
Emergency physician-performed bedside ultrasound of pyomyositis. 61
33778805 2021
12
Characterization of bacteriophage VVP001 and its application for the inhibition of Vibrio vulnificus causing seafood-borne diseases. 61
33279062 2021
13
Clinical characteristics that predict parotid abscess: An observational cohort study. 61
33777393 2021
14
Hospital at Home services: An inventory of fee-for-service payments to inform Medicare reimbursement. 61
33797753 2021
15
A rare cause of cervicomediastinal cellulitis: Oesophageal perforation case report. 61
33747496 2021
16
Transdermal Permeation of Caffeine Aided by Ionic Liquids: Potential for Enhanced Treatment of Cellulitis. 61
33796955 2021
17
Factors associated with melanoma-related limb lymphoedema. 61
33793386 2021
18
Blinking Dermatitis: A Case Report. 61
33798121 2021
19
Nasal-type extranodal NK/T-cell lymphoma presenting as recurrent periorbital cellulitis. 61
33795266 2021
20
Variation in UK guidelines for the first-line antimicrobial management of paediatric orbital cellulitis-time for national recommendations. 61
32989273 2021
21
Excluding Antibiotics in the Management of Nonoperative Orbital and Zygomatic Fractures. 61
33141770 2021
22
The association of apical periodontitis and type 2 diabetes mellitus: A large hospital network cross-sectional case-controlled study. 61
33795142 2021
23
Recurrent necrotizing cellulitis, multi-organ autoimmune disease and humoral immunodeficiency due to a novel NFKB1 frameshift mutation. 61
33486103 2021
24
Longitudinal impact of postmastectomy radiotherapy on arm lymphedema in patients with breast cancer: An analysis of serial changes in arm volume measured by infrared optoelectronic volumetry. 61
33667586 2021
25
A case of dropped head syndrome due to focal myositis that worsened with cellulitis and improved only by treatment of cellulitis. 61
33686913 2021
26
Silicone oil-associated orbital cellulitis with lipogranulomatous inflammation in the setting of HIV: a management challenge and clinicopathological correlation. 61
33687937 2021
27
Pyoderma gangrenosum associated with limited cutaneous systemic sclerosis: a rare case with literature review. 61
32676919 2021
28
Four-level Anterior Cervical Discectomy and Fusions: Results Following Multilevel Cervical Fusion With a Minimum 1-Year Follow-up. 61
33769972 2021
29
Analyzing the Efficacy of Isotretinoin in Treating Dissecting Cellulitis: A Literature Review and Meta-Analysis. 61
33387328 2021
30
The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. 61
33527618 2021
31
Risk Factors of Dissecting Cellulitis of the Scalp: A Case-Control Study. 61
33785386 2021
32
Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review. 61
31348693 2021
33
Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series. 61
33648906 2021
34
Safety of CPX4 Breast Tissue Expanders in Primary Reconstruction Patients. 61
33786255 2021
35
Skin and Soft Tissue Infections in Persons Who Inject Drugs. 61
33303334 2021
36
Treatment of Psoriasis in End-Stage Renal Disease Patients is Associated with Decreased Mortality: A Retrospective Cohort Study. 61
33798461 2021
37
Clinical Pathway With Single-Dose Long-Acting Intravenous Antibiotic Reduces Emergency Department Hospitalizations of Patients With Skin Infections. 61
33780567 2021
38
Investigating the Use of Denosumab in the Treatment of Acute Charcot Neuroarthropathy. 61
33472754 2021
39
Frequency of rare, serious donor reactions: International perspective. 61
33665853 2021
40
The Impact of Malnutrition on the Hospital and Infectious Outcomes of Patients Admitted With Alcoholic Hepatitis: 2011 to 2017 Analysis of US Hospitals. 61
33769393 2021
41
Ophthalmic manifestations in the COVID-19 clinical spectrum. 61
33595502 2021
42
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. 61
33673847 2021
43
Sex differences in hospitalized adult patients with cellulitis: A prospective, multicenter study. 61
33508477 2021
44
Abdominal Extension of Fournier Gangrene From Undiagnosed Crohn's Disease: A Case Report. 61
33742649 2021
45
An evaluation of sepsis in dentistry. 61
33772188 2021
46
[Bacterial acute non necrosing cellulitis (erysipelas) in adult]. 61
33176944 2021
47
Complicated sinusitis with sphenopalatine artery thrombosis in a COVID-19 patient: a case report. 61
33732419 2021
48
Outcomes of Vascularized Lymph Node Transplantation for the Treatment of Lymphedema. 61
33766726 2021
49
Ocular Syphilis Causing Panophthalmitis. 61
32732543 2021
50
A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors? 61
33655683 2021

Variations for Cellulitis

Expression for Cellulitis

Search GEO for disease gene expression data for Cellulitis.

Pathways for Cellulitis

Pathways related to Cellulitis according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 TNF RNASE3 IL6 IL5 IL1R1 FLT3
2
Show member pathways
13.76 TNF IL6 IL5 IL1R1 FLT4 FLT3
3
Show member pathways
13.6 TNF IL6 IL5 IL1R1 FLT4 FLT3
4
Show member pathways
13.47 TNF IL6 IL5 IL1R1 FLT4 FLT3
5
Show member pathways
13.29 TNF IL6 IL5 IL1R1 FLT3 CSF3
6
Show member pathways
13.26 TNF IL6 IL5 IL1R1 FLT4 FLT3
7
Show member pathways
13.22 TNF IL6 IL5 IL1R1 FLT4 CSF3
8
Show member pathways
12.52 TNF IL6 IL5 IL1R1 CD4
9
Show member pathways
12.27 TNF IL6 IL5 DEFB4A CSF3
10 12.26 TNF IL6 IL1R1 CD4
11
Show member pathways
12.25 TNF IL6 F2 CRP ALB
12
Show member pathways
12.24 RNASE3 DEFB4A CD4 CCR6 CAMP
13 12.17 TNF IL6 DEFB4A CAMP
14
Show member pathways
12.12 TNF IL6 IL1R1 DEFB4A
15 11.7 TNF IL6 IL5 FLT3 CSF3 CD4
16
Show member pathways
11.68 TNF IL6 CD4
17 11.6 TNF IL6 FLT3 CD4
18 11.56 TNF IL5 IL1R1 CD4 CCR6
19 11.52 TNF IL6 IL5 CCR6
20 11.48 TNF IL6 CSF3
21 11.47 TNF IL6 IL5 CSF3
22 11.45 IL6 IL5 CSF3
23 11.31 TNF IL6 IL1R1 CSF3
24 11.25 TNF IL6 IL5
25 11.16 TNF IL6 IL5 IL1R1 FLT3 CSF3
26 10.96 TNF IL6 IL5 FLT4 FLT3 CSF3
27 10.93 TNF IL6 CRP
28 10.82 TNF IL6 IL5 CSF3 CD4

GO Terms for Cellulitis

Cellular components related to Cellulitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF RNASE3 IL6 IL5 IL1R1 FLT4
2 external side of plasma membrane GO:0009897 9.65 TNF IL1R1 F2 CD4 CCR6
3 endoplasmic reticulum lumen GO:0005788 9.55 IL6 FLT3 F2 CD4 ALB
4 extracellular space GO:0005615 9.4 TNF RNASE3 IL6 IL5 GPT F2

Biological processes related to Cellulitis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 TNF IL6 IL5 IL1R1 CRP CHI3L1
2 positive regulation of cell proliferation GO:0008284 9.95 IL6 IL5 FLT4 FLT3 F2 CSF3
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 TNF FLT4 CHI3L1 CD4
4 cellular response to lipopolysaccharide GO:0071222 9.86 TNF IL6 CSF3 CAMP
5 positive regulation of protein phosphorylation GO:0001934 9.85 TNF FLT4 F2 CD4 CAMP
6 positive regulation of MAPK cascade GO:0043410 9.84 IL6 FLT4 FLT3 CD4
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 TNF IL6 IL5 CSF3
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 IL6 IL5 CSF3 CD4
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 TNF FLT3 F2 CSF3
10 positive regulation of kinase activity GO:0033674 9.78 FLT4 FLT3 CD4
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL6 FLT3
12 immune response GO:0006955 9.76 TNF IL6 IL5 IL1R1 DEFB4A CSF3
13 antimicrobial humoral response GO:0019730 9.75 RNASE3 DEFB4A CAMP
14 humoral immune response GO:0006959 9.74 TNF IL6 CCR6
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.73 RNASE3 F2 DEFB4A CAMP
16 acute-phase response GO:0006953 9.72 IL6 F2 CRP
17 defense response to Gram-negative bacterium GO:0050829 9.65 RNASE3 IL6 DEFB4A CD4 CAMP
18 positive regulation of JAK-STAT cascade GO:0046427 9.62 TNF IL6 IL5 F2
19 vascular endothelial growth factor production GO:0010573 9.58 TNF IL6
20 negative regulation of lipid storage GO:0010888 9.54 TNF IL6 CRP
21 cytokine-mediated signaling pathway GO:0019221 9.5 TNF IL6 IL5 IL1R1 FLT3 CSF3
22 defense response to Gram-positive bacterium GO:0050830 9.1 TNF RNASE3 IL6 DEFB4A CRP CAMP

Molecular functions related to Cellulitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL6 IL5 CSF3
2 growth factor activity GO:0008083 9.26 IL6 IL5 F2 CSF3
3 vascular endothelial growth factor-activated receptor activity GO:0005021 9.16 FLT4 FLT3
4 lipopolysaccharide binding GO:0001530 8.8 RNASE3 F2 CAMP

Sources for Cellulitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....